© Copyright 2026, All Rights Reserved
Predict progression from Mild Cognitive Impairment to Alzheimer's Disease; Identify patients for clinical trials based on early biomarkers; Enhance early intervention strategies for Alzheimer's patients; Monitor cognitive changes linked to mitochondrial dysfunction; Support personalized medicine approaches in neurodegenerative disease management.
Received funding from the European Union’s H2020 program; First Spanish laboratory accredited by the College of American Pathologists; ISO 13485 certified for quality management in medical devices.
Contact & Links:
Key Information:
Company Context: